A pilot study with ethyl bis (2,2-dimethyl-1-aziridinyl) phosphinate (AB-163) and radiation therapy.
暂无分享,去创建一个
[1] B. Amendola,et al. Radiation Therapy for Esophageal Cancer: The Medical College of Virginia Experience , 1980, Southern medical journal.
[2] G. Wampler,et al. Radiation potentiating effect of ethyl bis(2,2-dimethyl-1-aziridinyl) phosphinate (AB-163). , 1979, International journal of radiation oncology, biology, physics.
[3] M. Elkind. Fundamental questions in the combined use of radiation and chemicals in the treatment of cancer. , 1979, International journal of radiation oncology, biology, physics.
[4] J. A. Dunn,et al. Chemical mechanism of the radiation potentiating effects of 2,2-dimethylaziridine-type antitumor agents. , 1979, International journal of radiation oncology, biology, physics.
[5] I. Wodinsky,et al. Combined therapy with an aziridine derivative NSC 200724 (AB182) and radiation on an experimental leukemia. , 1979, International Journal of Radiation Oncology, Biology, Physics.
[6] J. Fowler,et al. Hypoxic cell sensitizers: early or late in fractionated therapy? , 1978, British Journal of Cancer.
[7] V. Marcial. Carcinoma of the cervix. Present status and future , 1977, Cancer.
[8] G. Wampler,et al. Synthfsis of bis(aziridinyl)phosphinyl-N-hydroxyurethane derivatives as antineoplastic agents. , 1975, Journal of medicinal chemistry.
[9] W. Regelson,et al. Laboratory and clinical evaluation of the radiation-potentiating activity of ethyl-N-bis (2,2-dimethylethylamidinophosphoro) carbamate (AB-132). , 1975, Journal of medicine.
[10] S. Levitt,et al. Effectiveness of radiation therapy in the treatment of carcinoma of the esophagus. A retrospective study. , 1970, The American journal of roentgenology, radium therapy, and nuclear medicine.
[11] A. Munson,et al. Studies on the chemistry, antitumor activity, and pharmacology of ethyl Di‐(2,2 ‐dimethyl)ethylenamido phosphate (AB‐163) , 1969, Journal of surgical oncology.
[12] A. Munson,et al. Synthesis and chemotherapeutic effects of ethyl bis-(2,2-dimethyl)-ethylenamido phosphate. A preliminary report. , 1967, Journal of pharmaceutical sciences.
[13] J. Webster,et al. Combined use of AB‐132 (Meturedepa, Turloc) and X irradiation in the management of advanced bronchogenic carcinoma , 1964, Cancer.
[14] B. Ma,et al. Treatment of carcinoma of the head and neck with AB-132 and radiation. , 1962 .